Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo delivery method may impact sleep and depression in GI cancer patients

NCT ID NCT06996483

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 198 adults with non-metastatic gastrointestinal cancer to see if taking chemotherapy as a pill (oral) or through a vein (IV) affects sleep quality and depression. Researchers measured sleep and mood before treatment, at 45 days, and at 90 days using standard questionnaires. The study did not change any treatment—it only observed and tracked these symptoms during routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

198 people

The number who actually took part.

Started

Jun 2025

Finished

Apr 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with non-metastatic gastrointestinal cancers who are receiving adjuvant chemotherapy with oral or intravenous 5-fluorouracil-based regimens at a tertiary cancer center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed non-metastatic gastrointestinal system cancer (e.g., colorectal, gastric) * Age ≥18 years * Planned to receive adjuvant chemotherapy containing 5-FU (either oral or IV) * ECOG performance status 0-2 * Provided informed consent Exclusion Criteria: * Patients with psychiatric disorders affecting sleep or mood * Receiving treatment for primary sleep disorders or depression * Prior chemotherapy or radiotherapy for the current diagnosis * Inability to complete the questionnaires due to cognitive or language barriers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression digestive system cancer digestive system neoplasm insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal neoplasms

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

  • Etlik City Hospital

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

  • Etlik City Hospital, Medical Oncology Department

    Ankara, Yenimahalle, 06210, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.